Published Technical Disclosure Archive

Enhanced Multivalent Molecules for Molecular Imaging and Radioimmunotherapy

Publication ID: 24-11857648_0001_PTD
Published: October 28, 2025
Category:Direct Improvements & Enhancements

Legal Citation

pr1or.art Inc., “Enhanced Multivalent Molecules for Molecular Imaging and Radioimmunotherapy,” Published Technical Disclosure No. 24-11857648_0001_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857648_0001_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,648.

Summary of the Inventive Concept

This invention relates to improved multivalent molecules for molecular imaging and/or targeted drug delivery, featuring enhanced stability, specificity, and binding affinity. The inventive concept addresses the limitations of existing multivalent molecules by introducing novel chelators, detectable labels, and spacer lengths.

Background and Problem Solved

The original patent disclosed a multivalent molecular imaging and/or targeted drug delivery method, wherein the multivalent molecule targeting different biomarkers carries the imaging label and/or drug. However, the existing method has limitations in terms of stability, specificity, and binding affinity. The new inventive concept solves these problems by introducing improved chelators, detectable labels, and optimized spacer lengths.

Detailed Description of the Inventive Concept

The enhanced multivalent molecule comprises a chelator with improved stability and specificity, a detectable label or therapeutic agent with enhanced binding affinity, and a novel spacer length optimized for improved cellular uptake and retention. The chelator can be selected from NOTA, NETA, CB-TE2A, CB-TE1A1P, TETA, Pycu2A, DiAmSar, DOTA, DTP, or other suitable chelating cores. The detectable label can be a radioactive isotope, a dye molecule, or other suitable label. The novel spacer length can be optimized using a high-throughput screening method. The inventive concept also encompasses a system, method, and kit for molecular imaging and/or therapy using the enhanced multivalent molecule.

Novelty and Inventive Step

The new inventive concept introduces novel chelators, detectable labels, and optimized spacer lengths, which are not obvious from the original patent. The improved stability, specificity, and binding affinity of the enhanced multivalent molecule provide a significant advantage over existing methods.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept include using different chelating cores, detectable labels, or spacer lengths. The inventive concept can also be adapted for use in various applications, such as cancer diagnosis and treatment, or infectious disease imaging.

Potential Commercial Applications and Market

The enhanced multivalent molecule has significant commercial potential in the fields of molecular imaging and targeted drug delivery. The inventive concept can be used in various industries, including pharmaceuticals, biotechnology, and medical imaging.

CPC Classifications

SectionClassGroup
A A61 A61K51/082
A A61 A61K9/51
A A61 A61K47/6893
A A61 A61K51/1027
C C07 C07D255/02
C C07 C07D257/02
C C07 C07K7/06
C C07 C07K7/64
C C07 C07K16/30
G G01 G01N33/5008
G G01 G01N33/60
C C07 C07K2319/00

Field of Art

Molecular imaging, radioimmunotherapy, and targeted drug delivery, with expertise in peptide chemistry, radioisotope labeling, and bioconjugate design. Requires advanced degrees in chemistry, biochemistry, or related fields with specialized knowledge of molecular targeting and diagnostic/therapeutic agent development

Person of Ordinary Skill (PHOSITA) Profile

A skilled researcher with expertise in designing multivalent molecular imaging compounds, understanding chelator chemistry, radioisotope labeling techniques, and bioconjugation strategies. Capable of systematic optimization of molecular structures and predicting potential variations

Obviousness Rationale

A person having ordinary skill would recognize that the PTD's proposed variations represent predictable engineering modifications to the source patent's core molecular imaging strategy. The disclosed improvements in chelator selection, spacer length, and label optimization are logical extensions of known techniques in molecular targeting. The variations represent routine experimentation within the established framework of multivalent molecular imaging compounds.

Obvious Combinations & Variations

Source Patent Element
Multivalent molecule with peptide components and chelator
PTD Variation
Introduction of novel spacer lengths and optimized conjugation strategies
Obviousness Reasoning
Spacer length optimization is a standard design parameter in bioconjugate chemistry, representing a predictable variation that a skilled practitioner would routinely explore to improve molecular performance
Source Patent Element
Chelator selection including NOTA, DOTA, TETA
PTD Variation
Emphasizing improved stability and specificity of chelating cores
Obviousness Reasoning
Selection and refinement of chelator performance is a known technique in radiopharmaceutical design, with finite predictable modifications available to a skilled researcher
Source Patent Element
Detectable labels including radioactive isotopes and dye molecules
PTD Variation
High-throughput screening method for identifying optimal label configurations
Obviousness Reasoning
Systematic screening of molecular labels is a standard approach in diagnostic agent development, representing an obvious extension of existing molecular engineering techniques
Source Patent Element
Molecular imaging compounds targeting multiple biomarkers
PTD Variation
Enhanced binding affinity through modified molecular architecture
Obviousness Reasoning
Improving molecular binding characteristics through structural modifications is a predictable outcome of routine research in targeted molecular design
35 U.S.C. § 103 Summary: Pursuant to 35 U.S.C. § 103, the variations disclosed in the instant publication would have been obvious to a person having ordinary skill in the art at the time of invention, with a reasonable expectation of success, when viewed in light of US Patent 11857648. The proposed molecular imaging compounds represent predictable engineering modifications that do not rise to the level of non-obvious innovation, thereby establishing this publication as anticipatory prior art against subsequent claims in the molecular targeting domain.

Original Patent Information

Patent NumberUS 11,857,648
TitleDimerization strategies and compounds for molecular imaging and/or radioimmunotherapy
Assignee(s)UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION